Oncology

Back to articles

Treatment outcomes improved in nonmetastatic pancreatic cancer

KEY POINT

In patients with nonmetastatic resected pancreatic adenocarcinoma, adjuvant chemotherapy with a modified FOLFIRINOX regimen led to significantly longer survival than treatment with gemcitabine (Gemzar—Lilly) but with a higher incidence of adverse effects, according to a study published in the New England Journal of Medicine.

SOURCES

Conroy T. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.

Kindler HL. A glimmer of hope for pancreatic cancer. N Engl J Med. 2018;379(25):2463–4.